Home » Posts tagged with » palbociclib
IBRANCE fails to meet primary endpoint in early breast cancer trial

IBRANCE fails to meet primary endpoint in early breast cancer trial

Pfizer said that the phase 3 PENELOPE-B clinical trial of IBRANCE (palbociclib) in early breast cancer failed to meet its primary endpoint. The collaborative late-stage trial is being held by the US pharma giant with the German Breast Group (GBG) sponsoring it. The primary endpoint of the PENELOPE-B clinical trial is improved invasive disease-free survival […]

October 11, 2020No CommentRead More

Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men

April 17, 2019 No Comment
Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men

New Ibrance FDA approval : The US Food and Drug Administration (FDA) has extended the approval of Pfizer breast cancer drug Ibrance (palbociclib) to cover the treatment of hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients. Latest Ibrance FDA approval Under the new indication approved […]

Continue reading …